Six injectable GLP-1 RAs are currently approved for the treatment of T2DM in Europe and in the USA
This is a preview of subscription content, access via your institution Access options Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription $32.99 / 30 days cancel any time Subscribe to this journal Receive 12 print issues and online access $259.00 per year only $21.58 per issue Buy this article Purchase on SpringerLink Instant access to the full article PDF
When the margin between success and failure is consistency over months, even modest improvements in how you feel day-to-day add up
Transdermal patches are being tested and developed for different medical applications, making way for FDA-approved GLP-1 transdermal patches in the future
This includes physician evaluation, personalized treatment plan, one-on-one guidance, metabolic reporting, prescription medication, and free shipping